

Supplementary Table 17. Time persistence effect on liver cirrhosis development following zoster vaccination

Time (yr)	Events, n (%)	aHR (95% CI)	
		Model 1 ^{a)}	Model 2 ^{b)}
< 1			
Unvaccinated	791 (0.11)	1.0 (reference)	1.0 (reference)
Vaccinated	598 (0.08)	0.75 (0.68 to 0.84) ^{c)}	0.75 (0.68 to 0.84) ^{c)}
1–2			
Unvaccinated	753 (0.10)	1.0 (reference)	1.0 (reference)
Vaccinated	588 (0.08)	0.78 (0.70 to 0.86) ^{c)}	0.78 (0.70 to 0.87) ^{c)}
2–4			
Unvaccinated	1,106 (0.15)	1.0 (reference)	1.0 (reference)
Vaccinated	749 (0.10)	0.71 (0.64 to 0.77) ^{c)}	0.71 (0.64 to 0.78) ^{c)}
4–6			
Unvaccinated	567 (0.08)	1.0 (reference)	1.0 (reference)
Vaccinated	374 (0.05)	0.77 (0.68 to 0.88) ^{c)}	0.75 (0.66 to 0.86) ^{c)}
6–8			
Unvaccinated	169 (0.02)	1.0 (reference)	1.0 (reference)
Vaccinated	93 (0.01)	0.71 (0.68 to 0.88) ^{c)}	0.66 (0.51 to 0.85) ^{c)}
≥ 8			
Unvaccinated	8 (0.001)	1.0 (reference)	1.0 (reference)
Vaccinated	3 (0.0004)	0.59 (0.16 to 2.24)	0.55 (0.14 to 2.11)

aHR, adjusted hazard ratio; CI, confidence interval.

^{a)}Models 1: adjusted for age (50–54, 55–59, 60–64, and ≥ 65 years) and sex.^{b)}Model 2: adjusted for age (50–54, 55–59, 60–64, and ≥ 65 years); sex; household income (low income, middle income, and high income); region of residence (urban and rural); Charlson comorbidity index (0, 1, and ≥ 2); obesity (underweight [$< 18.5 \text{ kg/m}^2$], normal [$18.5\text{--}22.9 \text{ kg/m}^2$], overweight [$23.0\text{--}24.9 \text{ kg/m}^2$], and obese [$\geq 25.0 \text{ kg/m}^2$]); blood pressure (systolic blood pressure $< 140 \text{ mmHg}$ and diastolic blood pressure $< 90 \text{ mmHg}$ and systolic blood pressure $\geq 140 \text{ mmHg}$ or diastolic blood pressure $\geq 90 \text{ mmHg}$); fasting blood glucose (< 100 and $\geq 100 \text{ mg/dL}$); glomerular filtration rate (< 60 , $60\text{--}89$, and $\geq 90 \text{ mL/min/1.73 m}^2$); smoking status (non-, ex-, and current smoker); alcohol consumption (drinks; < 1 , $1\text{--}2$, $3\text{--}4$, and ≥ 5 days per week); aerobic physical activity (sufficient and insufficient); and history of medication use for coronary artery disease, diabetes mellitus, dyslipidemia, and hypertension.^{c)}Significant differences ($p < 0.05$).